China’s biotechnology sector has recorded a sharp rise in international licensing deals during the opening months of 2026, highlighting the country’s growing influence in global pharmaceutical research and drug development. The total value of outlicensing agreements signed by Chinese biotech companies in the
China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
Chinese pharmaceutical companies signed a record US$136 billion worth of out licensing agreements in 2025, underscoring the rapid rise of China as a major source of innovative drug development and reshaping the global biopharmaceutical landscape. According to industry analysts, the total value of
